Clinical Trials
5 trialsNCT04106414 2025-10-14
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04047706 2025-06-29
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT03854032 2025-06-06
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Thomas Jefferson University
Phase 2 Active not recruiting
NCT03695250 2023-08-22
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
University of California, Davis
Phase 1/2 Terminated
NCT04007588 2020-02-05
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn